Background {#Sec1}
==========

Coronary artery bypass graft (CABG) surgery is a widely used surgical procedure to treat coronary artery disease (CAD). Saphenous vein grafts (SVGs) are commonly used in CABG due to the advantage of availability, although the patency rates of SVGs are lower than that for arterial grafts \[[@CR1]--[@CR3]\]. However, about 40--50% of the SVGs will be occluded within 10 to 15 years after CABG surgery \[[@CR1], [@CR4], [@CR5]\]. Newly developed atherosclerosis is the major reason for long-term poor prognosis \[[@CR3]\]. SVG disease (SVGD), defined as a stenosis of 50% or more of the SVGs excluding distal anastomotic occlusion, has become an important cause of morbidity and mortality for CAD patients after CABG surgery \[[@CR6], [@CR7]\].

Both repeat CABG and percutaneous coronary intervention (PCI) are available treatment options for the management of SVGD \[[@CR8]--[@CR10]\]. Due to increased morbidity and mortality associated with patients undergoing repeat CABG, SVG PCI is the preferred therapeutic option to restore vessel patency and improve symptoms for patients with SVGD \[[@CR11]--[@CR13]\]. PCI in patients with prior CABG comprises up to 6% of the total PCI performed in the United States \[[@CR14]\]. However, because of accelerated intimal proliferation and hyperplasia in venous conduits, SVG PCI is associated with increased risk of late failure and worse outcomes compared with native coronary artery interventions \[[@CR15], [@CR16]\]. Previous studies have shown that the incidence of major adverse cardiac events (MACEs) in patients who undergo bypass-graft PCI is significant higher than that in patients with native coronary artery PCI \[[@CR17], [@CR18]\]. It would be of particular interest to identify patients with poor prognosis after SVG PCI, which can be used for risk stratification and intervention guidance.

In recent years, intravascular ultrasound (IVUS) has been developed to identify vulnerable atherosclerotic plaques at high risk for coronary events. It was found that plaque characteristics (i.e., plaque burden, multiple plaque ruptures, lipid pool-like image and minimum luminal area) may be associated with no reflow phenomenon after PCI \[[@CR19]--[@CR22]\]. However, IVUS imposes limitations on identifying specific plaque components. Virtual histology-IVUS (VH-IVUS) is most widely used as it can assess both plaque composition and morphologic characteristics. VH-IVUS utilizes spectral and amplitude analysis of IVUS radiofrequency data to characterize plaque components, also suggesting the potential to identify vulnerable lesions \[[@CR23], [@CR24]\]. Moreover, several studies have demonstrated the independent relationship between VH-IVUS--defined plaque classification or plaque composition and MACEs \[[@CR25], [@CR26]\].

Considering similar pathophysiological mechanisms for CAD and SVGD, we hypothesized that plaque characteristics of SVG assessed by VH-IVUS might be associated with long-term clinical outcomes. However, data on plaque composition of SVG and its predictive values for clinical outcomes are still limited \[[@CR27]\]. Thus, we sought to investigate the relationship between plaque composition of SVG by VH-IVUS and clinical outcome in SVGD patients undergoing PCI, which could identify morphologic features that are predictive of post-PCI MACEs.

Methods and design {#Sec2}
==================

Study design and setting {#Sec3}
------------------------

The study is a prospective cohort study conducted in Tianjin Chest Hospital, Tianjin city, China. Patients with SVGD referred for PCI are invited to participate in the study and VH-IVUS is performed in culprit SVG before and after PCI. Patients are recruited consecutively by surgeons at the Cardiology Department of Tianjin Chest Hospital. These subjects will be followed up at 1, 6, 12, 24 and 36 months post-PCI to assess clinical outcomes. The flow diagram of the study and the detailed study procedures are illustrated in Fig. [1](#Fig1){ref-type="fig"}.Fig. 1Study flow chart

Participants {#Sec4}
------------

The patients to be included in the study should meet all of the following criteria: (1) aged 18--80 years; (2) a history of previous CABG surgery more than 1 year ago; (3) diagnosed as SVGD which is defined as at least one SVG ≥50% diameter stenosis; (4) plans for receiving PCI using drug-eluting stents; (5) willing to participate in the study and sign informed consent.

Patients will be excluded from the study if any of the following criteria is met: (1) acute myocardial infarction within the previous 7 days; (2) having any contraindication to aspirin, clopidogrel, heparin or stainless steel; (3) impaired renal or hepatic function; (4) history of cerebral stroke or ischemic cerebrovascular disease within 3 months; (5) history of gastrointestinal bleeding or hemoptysis in the previous 4 weeks; (6) pregnant or breastfeeding; (7) vasculitis or other non-atherosclerotic CAD; (8) other major illnesses that would expose the participant to unexpected risk: hematologic disorder, malignancy, etc.

Participants can withdraw from the study at any time without any adverse outcome on subsequent treatment; the reasons for withdrawal will be recorded. The investigator can also exclude a participant from the study for reasons including serious adverse events or poor compliance with research protocol.

Evaluation of the coronary angiography {#Sec5}
--------------------------------------

Coronary angiography is performed using angiography system with a flat-panel detector (Philips Allura Xper FD10, Philips Healthcare, Netherlands) according to the Judkins technique. Angiography of the in situ coronary artery is performed with 6F catheters through radial or femoral access, while Judkins R (JR) 4.0 is used as the first choice catheters for SVG angiography. The location of SVG is roughly determined according to previous CABG surgery procedure and it is displayed in at least two different projections. The presence of significant stenosis (≥50%) in at least one SVG is defined as SVGD.

VH-IVUS examination and plaque classification {#Sec6}
---------------------------------------------

After administration of heparin (100 U/Kg) and glyceryl trinitrate (100--200 μg), VH-IVUS is performed in SVG and other main coronary arteries before and after PCI. Data is obtained using a 20-MHz, 3.5-French EagleEye phased-array Gold catheter (Volcano Corporation, Rancho Cordova, California, USA) with motorized pullback (0.5 mm per second) from the most distal safe position to guide the catheter. The IVUS grey-scale and Virtual histology analyses are performed offline using the Volcano Image Analysis Software (version 3.0.394,Volcano Corporation, USA) and are not used for PCI guidance or subsequent management. Spectral and amplitude analyses of IVUS backscattered radiofrequency are performed by two experienced interventional cardiologists without knowledge of subsequent clinical events. Angiographic qualitative assessment and quantitative measurements are obtained for SVG. Quantitative IVUS measurements include cross-sectional areas (CAS) of the lumen, the external elastic membrane (EEM), and the plaque and media (EEM CAS minus lumen CAS), lesion length, plaque burden (plaque and media CAS divided by EEM CAS), and plaque volume. Qualitative IVUS assessments include plaque rupture (intraplaque cavity that communicated with the lumen with an overlying residual fibrous cap fragment) and characterization of lesions. On the basis of radiofrequency IVUS, plaque components and morphology are classified into the following four types: fibrous tissue (FT), fibrofatty (FF), necrotic core (NC), and dense calcium (DC). A lesion on IVUS imaging is defined as a plaque burden ≥40% in at least 3 consecutive frames. Consistent with published VH-IVUS classifications \[[@CR25], [@CR28]\], such lesions are classified as one of the following: 1) fibrotic plaque, mainly fibrous tissue with \< 10% confluent NC, \< 10% confluent DC, and \< 15% FF; 2) fibrocalcific plaque (FCa), mainly fibrous tissue with \> 10% confluent DC but \< 10% confluent NC; 3) pathologic intimal thickening (PIT), not meeting FCa plaque definitions and predominantly fibrous tissue; 4) fibroatheroma, \> 10% confluent NC, including thick-cap fibroatheroma (ThCFA) and thin-cap fibroatheroma (TCFA).

Baseline assessment and follow-up {#Sec7}
---------------------------------

After receiving written informed consent, clinical staff will collect demographic and clinical characteristics from all participants. Medical records will be reviewed and related clinical information will be extracted. The data to be collected at baseline include demographic characteristics, medical history (diabetes mellitus, hypertension, hyperlipaemia, stroke, arrhythmia, previous myocardial infarction, PCI or CABG surgery, and medicines for cardiovascular disease), physical examination, clinical presentation (vital signs at hospital admission, onset time of chest pain, duration of chest pain, cardiac function with Killip classification), and smoking history. Cardiac color ultrasound, coronary angiogram, pre- and post-PCI VH-IVUS and 18 lead ECG will be done and used for checking inclusion/exclusion criteria. In addition, blood samples will be collected for laboratory testing, including routine blood, blood biochemistry, fasting glucose, coagulation function, homocysteine, cardiac damage markers (lactic dehydrogenase, creatine kinase, B-type natriuretic peptide, hydroxybutyrate dehydrogenase, troponin H, myoglobin), and inflammatory factors.

Eligible participants will be hospitalized for PCI treatment. In the therapy phase, patients will receive PCI for SVGD using drug-eluting stents. Operation notes (operation date, bleeding volume, medication), thrombolysis in myocardial infarction (TIMI) flow, corrected TIMI frame count (CTFC) and adverse events will be recorded in detail.

All subjects will be followed up at 1, 6, 12, 24 and 36 months after surgery, with MACEs and adverse events assessment collected at each time by clinic visits or telephone interview.

Study endpoints {#Sec8}
---------------

The composite primary study endpoint is the incidence of MACEs after PCI for SVGD, including death from cardiac causes, non-fatal myocardial infarction, angina pectoris, target vessel revascularization (TVR) and hospitalization for heart failure.

Secondary endpoints are defined as: (1) the occurrence of the slow/no reflow, which is defined as thrombolysis in myocardial infarction (TIMI) grade 0, 1, or 2 flow within 24 h after SVG-PCI, despite successful treatment of the vessel obstruction; (2) myocardial infarction is defined as the onset of chest pain in combination with new, typical changes in the electrocardiogram and biochemical evidence of myocardial necrosis; (3)TVR is defined as a new revascularization procedure in the target vessel; (4)successful reperfusion is defined as TIMI flow grade 3 and less than 50% residual stenosis of SVG.

Sample size {#Sec9}
-----------

We expect CAS of plaque and media 2.9 ± 1.7 mm^2^ among patients with MACEs and 1.9 ± 1.5 mm^2^ among patients without MACEs. It is estimated that the incidence of MACEs is 20% in 3 years after PCI for SVGD. Assuming a 20% drop-out rate, a total of 175 participants are required to provide 80% power, with a two-sided type I error of 0.05.

Statistical analysis {#Sec10}
--------------------

Analyses will be made using SAS statistical software (version 9.3) by researchers at the Peking University Clinical Research Institute. Continuous variables will be expressed as mean ± standard deviation or median ± interquartile range (IQR), and t-test or Wilcoxon rank sum test will be used to compare the difference between groups. For categorical variables, the chi-square test/ Fisher's exact test will be performed. Time-to-event data (MACEs in 3 year after PCI) will be presented as Kaplan-Meier estimates and the primary outcome analysis will be carried out using univariate and multivariate Cox proportional hazards regression models. The ideal cut-off of quantitative indexes of VH-IVUS and the diagnostic accuracy will be determined by the receiver-operating characteristic curve (ROC). A *p*-value \< 0.05 will be considered statistically significant in all analyses.

Trial status {#Sec11}
------------

The first participant was enrolled in July 2017. As of August 2018, 67 participants have been enrolled and recruitment is ongoing in Tianjin Chest Hospital, China. Treatment and follow-up of all participants are planned to continue until December 2021.

Discussion {#Sec12}
==========

It has been indicated that plaque anatomy and composition identified by VH-IVUS is a predictor of long-term clinical outcomes in patients undergoing PCI. However, there have been few studies investigating the relationship between plaque composition of SVG by VH-IVUS and clinical outcome in SVGD patients undergoing PCI. PCI is a widely performed surgical procedure for SVGD patients. Considering the higher risk in conducting PCI among SVGD patients, it is necessary to explore the cardiovascular factors predicting the clinical outcome of PCI, which can be used for risk stratification and intervention guidance. In this prospective cohort study, we will identify atherosclerotic plaque components and characteristics in SVGD patients undergoing PCI and predict the long-term clinical outcomes identified with VH-IVUS.

Multiple novel intravascular imaging technologies have been developed to help identify high risk plaque characteristics in predicting cardiovascular adverse events \[[@CR22], [@CR29], [@CR30]\]. Young Joon Hong et al. investigated the relationship between intravascular IVUS findings and the no-reflow phenomenon after PCI for SVGD \[[@CR22]\]. But IVUS has limited value for identifying specific plaque components \[[@CR31]\]. Computed tomography (CT) is routinely used for coronary angiography and can identify high risk features of plaques. Daniel R. Obaid et al. found that plaque components and classifications based on CT could not reliably classify plaques and identify TCFA \[[@CR30]\]. With the highest spatial resolution, optical coherence tomography (OCT) has emerged as an important imaging modality for intracoronary evaluation \[[@CR32]\]. The direct comparison between VH-IVUS and OCT by Brown et al. found that both VH-IVUS and OCT could identify advanced coronary plaques and that combined VH-IVUS/OCT was better than either alone \[[@CR33]\]. However, OCT has a low signal penetration through lipid or necrotic core, and cannot adequately acquire images of the whole vessels with large lumen diameter or large necrotic core \[[@CR29], [@CR34]\]. This presents a problem for imaging of large vessels including vein grafts. The presence of macrophages, foam cells, microcalcifications, or hemosiderin, often co-existent with the necrotic core, could be adverse to accurate OCT assessment of lipidic plaque \[[@CR29], [@CR34]\]. VH-IVUS, which has become clinically available, can assess both plaque morphology and tissue characteristics using spectral and amplitude analysis of backscattered radiofrequency ultrasound signal. With different plaque components exhibiting a defined spectrum, VH-IVUS can classify atherosclerotic plaque into four types: FT, FF, NC, and DC \[[@CR35], [@CR36]\]. The radiofrequency signal is mathematically transformed into a color-coded representation, including lipid, fibrous tissue, calcification, and necrotic core \[[@CR37]\]. Thus, VH-IVUS can identify atherosclerotic plaques exactly like histopathology.

Some meta-analysis studies have found that the relationship between absolute volume of NC components on VH-IVUS imaging and distal embolization after PCI in acute coronary syndrome (ACS) patients \[[@CR35], [@CR38]\]. Previous studies have demonstrated that TCFA, plaque burden, and minimum luminal area are associated with MACEs among ACS patients undergoing PCI \[[@CR25], [@CR26]\]. The VIVA (VH-IVUS in Vulnerable Atherosclerosis) Study showed that VH-IVUS TCFA was associated with nonrestenotic and total MACEs on individual plaque or whole patient analysis \[[@CR26]\]. It was reported by the Providing Regional Observations to Study Predictors of Events in the Coronary Tree (PROSPECT) study that plaque burden \> 70%, minimum luminal area \< 4 mm^2^, and VH-IVUS TCFA were the independent predictors of nonculprit lesion--related events. However, there are limited studies investigating the associations of degenerative lesions or plaque components of SVGD with clinical outcomes using VH-IVUS. Man-Hong Jim et al. sought to report the VH-IVUS findings in degenerative aortocoronary SVG lesions and correlate plaque compositions with clinical characteristics \[[@CR39]\]. Lesions with a plaque burden ≥70% was found to be positively correlated with FF tissue, but negatively correlated with DC \[[@CR39]\]. However, it is a cross-sectional study, the temporary relationship between VH-IVUS findings and clinical characteristics cannot be determined. As far as the authors know, there is currently no study exploring the relationship between VH-IVUS defined atherosclerotic plaque components and clinical outcomes in SVGD patients undergoing PCI.

The current study is subject to several limitations. This is an observational cohort study, confounding effects cannot be ruled out entirely. However, the multivariate Cox proportional regression model will be used to determine the independent effects of VH-IVUS findings on long-term clinical outcomes after adjusting for the impact of baseline characteristics. Second, participants with SVGD who are enrolled in a single center (Cardiovascular Institute, Tianjin Chest Hospital) may not represent the population in China. However, we speculate that the relationship between VH-IVUS findings and clinical outcomes should persist in other SVGD patients undergoing PCI, but with varying magnitudes of association. Third, although VH-IVUS is a widely used method in clinical setting, VH-IVUS has some technological limitations. VH-IVUS TCFA is not equivalent to histopathologic definitions and VH-IVUS tend to over-estimate TCFA compared with histology.

Conclusion {#Sec13}
==========

The proposed prospective cohort study aims to investigate whether plaque characteristics and components of culprit SVG lesion assessed by VH-IVUS could predict subsequent clinical outcome after PCI among SVGD patients. Once our hypothesis is confirmed, an innovative prediction tool of clinical outcomes can be created, which may lead to the development of new methods of risk stratification and intervention guidance.

ACS

:   Acute coronary syndrome

CABG

:   coronary artery bypass grafting

CAD

:   coronary artery disease

CAS

:   cross-sectional areas

CT

:   Computed tomography

CTFC

:   Corrected TIMI frame count

DC

:   dense calcium

EEM

:   external elastic membrane

FCa

:   fibrocalcific plaque

FF

:   fibrofatty

FT

:   fibrous tissue

IVUS

:   intravascular ultrasound

MACEs

:   major adverse cardiac events

NC

:   necrotic core

OCT

:   Optical coherence tomography

PCI

:   percutaneous coronary intervention

PIT

:   Pathologic intimal thickening

PROSPECT

:   Providing Regional Observations to Study Predictors of Events in the Coronary Tree

ROC

:   Receiver-operating characteristic curve

SVGD

:   saphenous vein grafts disease

SVGs

:   saphenous vein grafts

TCFA

:   Thin-cap fibroatheroma

ThCFA

:   Thick-cap fibroatheroma

TIMI

:   Thrombolysis in myocardial infarction

TLR

:   target lesion revascularization

TVR

:   target vessel revascularization

VH-IVUS

:   virtual histology intravascular ultrasound

The authors thank all of the study participants for their great effort. Furthermore, we wish to thank the research staffs for their efforts in the study.

Funding {#FPar3}
=======

This research was funded by the Key Project of Scientific and Technological Support Plan of Tianjin in 2016 (No.:16YFZCSY00800) and the Key Project of Healthcare Industry of Tianjin in 2015 (No.: 15KG128). However, study sponsor doesn't involve in any activities related with study except monitoring.

Availability of data and materials {#FPar4}
==================================

The datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request.

Data sharing statement {#FPar1}
======================

Not applicable.

YL, JG, XL, HBW, ZGG, JYX, JXW, KHR and BS developed the protocol for this project. GJ and YL were the principal investigators and managed the protocol. ZGG and JYX were responsible for data collection and management. JXW and BS were responsible for epidemiological investigations and laboratory testing. XL, HBW and KHR performed all statistical analysis. YL, JG, XL, HBW, ZGG, JYX, JXW, KHR and BS were involved in the initial draft of the manuscript and writing it. JG, HBW and KHR assisted with writing and editing of the manuscript. The manuscript was amended based on comments from all authors. All authors read and approved the final manuscript.

Ethics approval and consent to participate {#FPar2}
==========================================

The study protocol has been approved by the Institutional Review Boards of Tianjin Chest Hospital and the study will be conducted in accordance with Declaration of Helsinki. Written informed consent is signed by all the participants. The study is also registered at [www.clinicaltrials.gov](http://www.clinicaltrials.gov) (NCT03175952) on June 5, 2017.

Consent for publication {#FPar5}
=======================

Not applicable.

Competing interests {#FPar6}
===================

The authors declare that they have no competing interests.

Publisher's Note {#FPar7}
================

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
